Repatha Was Almost Derailed By Formulation Bridging Concerns
Executive Summary
FDA's worries about sufficiency of long-term safety data were exacerbated by 'weak' bridging data between two formulations; agency decided against refuse-to-file action but directed Amgen to immediately begin new PK/PD study.
You may also be interested in...
Behind The Approval Letter: Drug Review Profiles
A listing of the Drug Review Profile series articles published in the Pink Sheet.
Praluent Sponsors Set Tone For PCSK9 Labeling, Post-Marketing Negotiations
Sanofi and Regeneron's 'extended negotiations' with FDA on requirements would later apply to Amgen's Repatha.
Liver Injury Case Sparked Flurry Of Concern Late In Praluent Review
MedWatch report of hepatotoxicity prompted two 'urgent information requests' to sponsors a month before alirocumab user fee goal date.